Oddo BHF - Sartorius Stedim Biotech SA (DIM) Sartorius Stedim Biotech : Q4 review – good finish, strong order intake, still only qualitative guidance

Report

Oddo BHF

Oliver Metzger

Sartorius Stedim Biotech : Q4 review – good finish, strong order intake, still only qualitative guidance

28/01/2025 1 EN

Underlying

Sartorius Stedim Biotech SA

Sartorius Stedim Biotech is a provider of equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Co.'s solutions cover fermentation, filtration, purification, fluid management and lab technologies and membrane chromatography, including various conventional lab products to biopharmaceutical laboratories. Co.'s technologies, products and services are used to develop and manufacture medications and vaccines using biological methods. Co.'s products covers all upstream and downstream steps in the production of active pharmaceutical ingredients. It specializes in single-use products and offers technical consulting and services.

See profile

FR0013154002 Euronext Paris France

Provider

Oddo BHF

Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

See profile

Analysts

Oliver Metzger

Other Reports on these Companies

EQUITS GmbH

Vorsichtige Guidance FY 25 sieht moderates, profitables Wachstum – langsamer Start in FY 25 erwartet

Der scheidende CEO plant die 1. Guidance FY 25 nur qualitativ und in „bewusst vorsichtigem Grundton“ (Konkretisierung am 16.04.25). Die Visibilität „werde besser“. Lagerabbau und Investitionszurückhaltung seien in Q4/24 überwunden, ein stabiles positives Momentum sei aber noch nicht erkennbar.

EUR 290.00

15h 15h 4 DE

EQUITS GmbH

Cautious FY 25 guidance sees moderate, profitable growth – slow start expected in FY 25

The outgoing CEO plans to give only a qualitative outlook for the first time in FY 25 and in a “deliberately cautious tone” (more details on April 16, 2025). Visibility “will improve”. Inventory reductions and investment restraint were overcome in Q4/24, but a stable positive momentum is not yet visible.

EUR 290.00

15h / 4m 15h / 4m 4 EN

New Street Research

Sartorius Stedim - Upgrade to HOLD (HOLD [SELL], TP EUR230 [120], 9pgs)

We upgrade Stedim to Hold after a strong Q4 order book and signs of improvement across the bioprocessing industry. Whilst the Stedim valuation seems very stretched to us, we feel comfortable sales can grow HSD this year with a 2% FX tailwind, improving order book & signs that many customers are now back to normal ordering patterns. Our proprietary biologic demand model shows that demand should grow 9% this year but is slowing over the coming years & our yield analysis shows that improving yields will be a drag on growth. However, given the current market stabilisation & improving trends, we do...

EUR 4798.50

19h / 47m 19h / 47m 1 EN

ODDO : 2025 : potentiellement un meilleur cru que 2024

L’année 2025 verra, selon nous, une poursuite de la croissance du CA (5% estimé vs 1.5% en 2024e) et de l’amélioration de la marge (53 pb vs 14 pb en 2024e), à l’exception possible de quelques sociétés (marge optimisée ou risque lié aux hausses des droits de douane). Si quelques thématiques devraient rester inchangées (exposition USA, Green Capex, datacenters, etc), d’autres émergeront (construction, discrete automation) ou accélèreront (semiconducteurs) au cours de l’année. Dans ce contexte, nos top picks sont Alstom, Assa Abloy, Siemens et SKF et nous relevons notre recommandation sur Epiroc...

12h / 52m 12h / 52m 1 FR

Delphine Brault ... (+2)

Delphine Brault
Quentin Borie

ODDO : 2025: set to potentially be a better year than 2024

2025 is in our view likely to see sales continue to grow (5% estimated vs 1.5% in 2024e) and margins continue to improve (53bp vs 14bp in 2024e), with the possible exception of a few companies (optimised margins or tariff risk). While some themes are likely to endure (US exposure, green capex, data centres, etc.), others will emerge (construction, discrete automation) or accelerate (semiconductors) over the year. In this context, our Top Picks are Alstom, Assa Abloy, Siemens and SKF. And we upgrade our rating on Epiroc (to Neutral) and downgrade dormakaba (to Neutral) and Sandvik (to Underperf...

12h / 58m 12h / 58m 1 EN

Florent Laroche-Joubert ... (+2)

Florent Laroche-Joubert
Roy Külter

ODDO : La baisse des taux d’intérêt favorise l’immobilier : nos top picks pour 2025

Le maintien d’un environnement baissier des taux d’intérêt devrait être porteur pour le secteur immobilier en 2025 et lui permettre de continuer à surperformer. Dans ce contexte, nous privilégions le commerce et le résidentiel allemand , qualifiés de « safe haven » et plus spécifiquement Covivio, CTP, Merlin Properties, URW, Vonovia et Xior Student Housing pour un potentiel moyen de +30%. Elles sont les plus à même pour nous d’exécuter leur stratégie de croissance / repositionnement. Nous abaissons notre opinion à Sous-performance sur Branicks, Cofinimmo, Icade et Patrizia et procédons à 26 aj...

13h / 4m 13h / 4m 1 FR

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN